Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chris Polman

Showing results (21-30 of 41) with videos related to

Pageof 5
Sort By:
Clinical Biochemistry|April 4, 2009
Increase of uric acid and purine compounds in biological fluids of multiple sclerosis patientsAngela M Amorini, Axel Petzold, Barbara Tavazzi, et al.
Journal of Neurology|October 20, 2011
Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MSBianca Weinstock-Guttman, Steven L Galetta, Gavin Giovannoni, et al.
Archives of Neurology|May 13, 2009
A single, early magnetic resonance imaging study in the diagnosis of multiple sclerosisAlex Rovira, Josephine Swanton, Mar Tintoré, et al.
Journal of Neurology|February 16, 2008
A three-year, multi-parametric MRI study in patients at presentation with CISMaria A Rocca, Federica Agosta, Maria P Sormani, et al.
Radiology|September 24, 2004
The spinal cord in multiple sclerosis: relationship of high-spatial-resolution quantitative MR imaging findings to histopathologic resultsJoseph C J Bot, Erwin L A Blezer, Wouter Kamphorst, et al.
Annals of Neurology|April 3, 2008
Predicting progression in primary progressive multiple sclerosis: a 10-year multicenter studyZhaleh Khaleeli, Olga Ciccarelli, Francesco Manfredonia, et al.
Journal of Neurology|November 16, 2007
Subgroups of the BENEFIT study: risk of developing MS and treatment effect of interferon beta-1bChris Polman, Ludwig Kappos, Mark S Freedman, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 21, 2012
Protective effect of an elastase inhibitor in a neuromyelitis optica-like disease driven by a peptide of myelin oligodendroglial glycoproteinKatja Herges, Brigit A de Jong, Ilan Kolkowitz, et al.
The Lancet. Neurology|July 10, 2007
MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective studyJosephine K Swanton, Alex Rovira, Mar Tintore, et al.
The Lancet. Neurology|February 21, 2006
MRI criteria for dissemination in space in patients with clinically isolated syndromes: a multicentre follow-up studyTijmen Korteweg, Mar Tintoré, Bernard Uitdehaag, et al.
Pageof 5

Showing results (21-30 of 41) with videos related to

Sort By:
Pageof 5
Clinical Biochemistry|April 4, 2009
Increase of uric acid and purine compounds in biological fluids of multiple sclerosis patientsAngela M Amorini, Axel Petzold, Barbara Tavazzi, et al.
Journal of Neurology|October 20, 2011
Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MSBianca Weinstock-Guttman, Steven L Galetta, Gavin Giovannoni, et al.
Archives of Neurology|May 13, 2009
A single, early magnetic resonance imaging study in the diagnosis of multiple sclerosisAlex Rovira, Josephine Swanton, Mar Tintoré, et al.
Journal of Neurology|February 16, 2008
A three-year, multi-parametric MRI study in patients at presentation with CISMaria A Rocca, Federica Agosta, Maria P Sormani, et al.
Radiology|September 24, 2004
The spinal cord in multiple sclerosis: relationship of high-spatial-resolution quantitative MR imaging findings to histopathologic resultsJoseph C J Bot, Erwin L A Blezer, Wouter Kamphorst, et al.
Annals of Neurology|April 3, 2008
Predicting progression in primary progressive multiple sclerosis: a 10-year multicenter studyZhaleh Khaleeli, Olga Ciccarelli, Francesco Manfredonia, et al.
Journal of Neurology|November 16, 2007
Subgroups of the BENEFIT study: risk of developing MS and treatment effect of interferon beta-1bChris Polman, Ludwig Kappos, Mark S Freedman, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 21, 2012
Protective effect of an elastase inhibitor in a neuromyelitis optica-like disease driven by a peptide of myelin oligodendroglial glycoproteinKatja Herges, Brigit A de Jong, Ilan Kolkowitz, et al.
The Lancet. Neurology|July 10, 2007
MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective studyJosephine K Swanton, Alex Rovira, Mar Tintore, et al.
The Lancet. Neurology|February 21, 2006
MRI criteria for dissemination in space in patients with clinically isolated syndromes: a multicentre follow-up studyTijmen Korteweg, Mar Tintoré, Bernard Uitdehaag, et al.
Pageof 5